Showing 7511-7520 of 8649 results for "".
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- Study Examines ImprimisRx’s Proprietary Klarity-C for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/multicenter-retrospective-study-examines-imprimisrxs-proprietary-klarity-c-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2479218/ImprimisRx, a wholly owned subsidiary of Harrow Health, announced that a study of its Klarity-C Drops (cyclosporine 0.1% ophthalmic emulsion PF) has been published in the peer-reviewed journal, Clinical Ophthalmology.1 Klarity-C is a compounded preservative-free cyclosporine e
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19https://modernod.com/news/gensight-biologics-provides-2021-operations-update-in-the-context-of-covid-19/2479212/GenSight Biologics provided an update on the impact of COVID-19 on its operations in 2021. “It has been slightly over a year since we had to adjust our operations to the COVID-19 situation and provided you with an update on our activities. Although conditions have improved in many regions,
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d